前列舒通胶囊联合非那雄胺对良性前列腺增生症的疗效观察
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:


Curative efficacy of Qianlie Shutong Capsules combined with finasteride in treatment of benign prostatic hyperplasia
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
    摘要:

    【摘要】目的 讨前列舒通胶囊联合非那雄胺治疗良性前列腺增生症的疗效及相关指标的影响。方法 收集2015年4月~2016年4月我院收治的90例良性前列腺增生症患者, 分为实验组和对照组, 每组各45例。两组患者均给予常规检查、控制感染、积极治疗原发病等, 对照组在此基础上采用非那雄胺治疗(5mg/次, 1次/天)。观察组在对照组的基础上采用前列舒通胶囊治疗(3粒/次, 3次/天)。两组治疗疗程均为2个月。观察两组治疗疗效, 前列腺体积、残余尿量、最大尿流率, IPSS、NIHCPSI评分, 肿瘤坏死因子α(TNFα)、白细胞介素17(IL17)、白细胞介素10(IL10)水平。结果 实验组总有效率显著高于对照组(P<005);前列腺体积、残余尿量显著低于对照组(P<005), 最大尿流率显著高于对照组(P<005);IPSS、NIHCPSI评分显著低于对照组(P<005);TNFα、IL17水平显著低于对照组(P<005); IL10水平显著高于对照组(P<005)。结论 前列舒通胶囊联合非那雄胺对良性前列腺增生症的疗效显著, 可有效改善临床症状, 无明显并发症, 具有一定的安全性, 还可调节炎症因子水平, 可在临床推广应用。

    Abstract:

    【Abstract】Objective To study curative efficacy of Qianlie Shutong Capsules combined with finasteride in treatment of benign prostatic hyperplasia.Methods 90 patients of benign prostatic hyperplasia received therapy from April 2015 to April 2016 in our hospital were selected as research objects. According to the draw method, the patients were divided into control group and experimental group. Two groups of patients were given routine examination, infection control, active treatment of primary diseases and other treatment. The control group was on this basis, treated with finasteride, 5mg per day, 1 time a day. The experimental group was based on the control group, treated with Qianlie Shutong Capsules, take 3 pills each time, 3 times a day. The two groups were treated for 2 months. The prostate volume, residual urine volume, maximum urinary flow rate, IPSS and NIHCPSI scores, TNF, IL17 and IL10 levels were evaluated of two groups were compared.Results The total effective rate of the experimental group was significantly higher than that of the control group[9333%(42/45)vs7333%(33/45)](P<005). The volume and residual urine volume of prostate of the experimental group were significantly lower than the control group[(2736±803)cm3 vs(3248±931)cm3, (2037±671)mL vs(2643±804)mL](P<005). The maximum urinary flow rate of the experimental group was significantly higher than that of the control group[(1709±327)mL·s1 vs(1462±306)mL·s1](P<005). IPSS and NIHCPSI were of the experimental group were significantly lower than that of the control group(P<005). TNFα and IL17 of the experimental group were significantly lower than that of the control group[(2319±838)μg/L vs(3049±1052)μg/L, (1037±236)μg/L vs(2476±324)μg/L](P<005). IL10 of the experimental group was significantly higher than that of the control group[(2153±521)μg/L vs(1769±402)μg/L](P<005).Conclusion Qianlie Shutong Capsules combined with finasteride is effective for benign prostatic hyperplasia, which can effectively improve the clinical symptoms, no obvious complications, has certain safety, and can also adjust the level of inflammatory factors.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2018-03-05
您是第位访问者
版权所有:《西部医学》编辑部     蜀ICP备18038379号-4
地址:四川省成都市武侯区小天竺街75号财富国际18F-1号    邮政编码:610041
电话:028-85570072/85588403    E-mail:xbyxqk@163.com
技术支持:北京勤云科技发展有限公司